Table 3 Patient characteristics
Characteristics | All | sarcopenic patients | non-sarcopenic patients | P-value |
|---|---|---|---|---|
(n = 101) | (n = 35) | (n = 65) | ||
(mean ± SD) or | (mean ± SD) or | (mean ± SD) or | ||
(n, %) | (n, %) | (n, %) | ||
Age (years) | 79.7 ± 4.0 | 82.1 ± 4.5 | 78.4 ± 3.1 | * < 0.001 |
Gender | ||||
male | 64 (63%) | 14 (40%) | 49 (75%) | # < 0.001 |
female | 37 (37%) | 21 (60%) | 16 (25%) | # < 0.001 |
Number of medications (regularly) | 9.0 ± 3.0 | 10.1 ± 3.4 | 8.5 ± 2.6 | *0.009 |
Number of medications (p.r.n.) | 1.3 ± 1.4 | 1.1 ± 1.3 | 1.4 ± 1.4 | *0.231 |
Level of care | 24 (24%) | 16 (46%) | 8 (12%) | #0.001 |
Situation of living | ||||
Living alone | 27 (27%) | 17 (49%) | 10 (15%) | # < 0.001 |
Diagnosisa | ||||
CABG-surgery | 44 (33%) | 7 (18%) | 36 (39%) | #0.001 |
Valve surgery (e.g., mitral valve replacement) | 50 (38%) | 16 (41%) | 34 (37%) | #0.373 |
Valve intervention (e.g., MitraClip, TAVI) | 20 (15%) | 13 (33%) | 7 (8%) | #0.002 |
Concomitant diseases | ||||
Coronary artery disease | 73 (72%) | 23 (66%) | 49 (75%) | #0.304 |
Myocard infarction | 21 (21%) | 5 (14%) | 16 (25%) | #0.226 |
Heart failure | 75 (74%) | 28 (80%) | 46 (71%) | #0.315 |
Cardiac arrhythmias | 64 (63%) | 25 (71%) | 38 (59%) | #0.200 |
Stroke | 10 (10%) | 4 (11%) | 6 (9%) | #0.727 |
Peripheral artery disease | 12 (12%) | 6 (9%) | #0.246 | |
Hypertension | 92 (91%) | 31 (89%) | 60 (92%) | #0.533 |
Diabetes mellitus | 27 (27%) | 8 (23%) | 16 (25%) | #0.844 |
Asthma bronchiale | 10 (10%) | 6 (17%) | 4 (6%) | #0.081 |
Chronic lung disease (e.g. COPD) | 13 (13%) | 6 (17%) | 7 (11%) | #0.366 |
Rheumatism | 6 (6%) | 2 (6%) | 4 (6%) | #0.930 |
Athrosis | 34 (34%) | 18 (51%) | 16 (25%) | #0.007 |
Gout | 15 (15%) | 8 (23%) | 7 (11%) | #0.106 |
Fractures | 51 (51%) | 21 (60%) | 30 (46%) | #0.186 |
Chronic pain | 16 (16%) | 10 (29%) | 5 (8%) | #0.005 |
Kidney disease | 27 (27%) | 13 (37%) | 14 (22%) | #0.076 |
Cancer | ||||
Breast | 6 (6%) | 2 (6%) | 4 (6%) | #0.930 |
Prostate | 12 (12%) | 2 (6%) | 10 (15%) | #0.156 |
Colon | 3 (3%) | 2 (6%) | 1 (2%) | #0.243 |
Baseline Assessments | ||||
KATZ-Index (PPF) | 5.7 ± 0.9 (17.8%) | 5.1 ± 1.3 (38.9%) | 5.9 ± 0.3 (6.2%) | *0.005† |
Handgrip strength (kg, PPF) | 24.9 ± 9.9 | 17.5 ± 8.3 | 28.7 ± 8.3 | * < 0.001† |
(♂: 37.5%; ♀: 56.8%) | (♂: 60.0%; ♀: 71.4%) | (♂: 30.6%; ♀: 37.5%) | ||
SPPB score (PPF) | 7.5 ± 3.3 (57.4%) | 4.7 ± 2.8 (94.4%) | 9.0 ± 2.5 (36.9%) | * < 0.001† |
6MWD (m, PPF) | 288.8 ± 136.5 (43.6%) | 186.5 ± 120.7 (75.0%) | 342.6 ± 112.4 (26.2%) | * < 0.001† |
CFS (PPF) | 3.2 ± 1.4 (41.6%) | 4.1 ± 1.0 (66.6%) | 2.7 ± 1.3 (27.6%) | * < 0.001† |